ArticleCost effectiveness and resource allocation : C/E2024

A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial.

Jiahui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.